Novel agents in the Canadian therapeutic landscape of chronic lymphocytic leukemia
Bibliographic record
Abstract
In this brief commentary, we discuss oral novel agents within in the armementarium of therapeutic options for Canadian patients with chronic lymphocytic leukemia (CLL). Previously limited to chemotherapy, the Canadian patient with relapsed or refractory CLL has the option of treatment with B-cell receptor inhibitors ibrutinib or idelalisib (combined with rituximab), both individually showing superiority to anti-CD20 monoclonal antibody comparators regardless of high-risk deletion 17p (del(17p)) status in phase 3 clinical trials . BCL2-inhibitor venetoclax shows impressive efficacy for previously-treated patients with del(17p), but though approved, it is not yet funded. For treatment-naïve patients, ibrutinib has proven superior to chemotherapy for those over 65 with comorbidities, but its role remains to be seen for the young and/or fit. Whereas oral novel agents are generally well-tolerated, some side effects , such as infection, hemorrhage , cardiac arrhythmias and tumour lysis syndrome , can be severe, therefore expert clinical vigilance is essential. Regarding sequencing of these agents, most patients failing ibrutinib or idelalisib do respond to venetoclax . While future studies using combinations of novel agents may eventually obviate the use of chemotherapy for CLL, regimens that can be stopped when minimal residual disease is achieved, such as venetoclax, are particularly relevant for our publicly-funded health care system. For Canadian CLL patients, the availability of oral novel agents has greatly expanded treatment options and is improving outcomes.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.008 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.002 |
| Science and technology studies | 0.003 | 0.003 |
| Scholarly communication | 0.004 | 0.002 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.007 | 0.009 |
| Insufficient payload (model declined to judge) | 0.006 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".